Sim&Cure
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sim&Cure - overview
Established
2014
Location
Montpellier, -, France
Primary Industry
Medical Devices & Equipment
About
Sim&Cure, SA develops advanced solutions utilizing Digital Twin and AI technologies to significantly improve the treatment of brain aneurysms and enhance procedural success in neurovascular interventions. Founded in 2014 in France, Sim&Cure, SA focuses on innovative solutions for treating brain aneurysms. The company has engaged in three deals, with the most recent being a Series A funding round on November 28, 2025, raising EUR 2. 3 mn led by Elaia Partners with participatopn from IT-Translation, Irdi Capital Investissement, SWEN Capital Partners, Sofilaro, Tudigo, and Holnest.
Mathieu Sanchez serves as both the founder and CEO, leading the company's strategic direction. Sim&Cure specializes in advanced solutions for brain aneurysm treatment, leveraging Digital Twin and AI technologies to improve patient care. Their core offerings include sophisticated tools designed to support endovascular procedures critical for aneurysm treatment. These solutions enhance healthcare professionals' capabilities to optimize patient outcomes during interventions, serving hospitals, clinics, and neurovascular specialists globally, with a significant presence in North America, Europe, and parts of Asia-Pacific.
In 2020, Sim&Cure reported revenue of EUR 1,249,270. 20 with an EBITDA of EUR -964,853. 30. The revenue generation model is primarily B2B, involving direct sales to healthcare institutions and medtech companies, as well as subscription models for software updates and support services.
With the recent Series A funding of EUR 2. 3 mn raised on November 28, 2025, Sim&Cure plans to expand into Asia-Pacific including China, speed up development of its neurovascular simulation software, and grow its R&D and sales teams.
Current Investors
Elaia Partners, IT-Translation, SWEN Capital Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare IT, Medical Devices & Equipment, Medical Software
Website
www.sim-and-cure.com
Verticals
Artificial Intelligence, Cloud Computing, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Sim&Cure - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 65,479 | 197,478 | 324,906 | 618,071 | 913,908 | 1,093,925 | - | - | - | - |
| % Revenue Growth (YoY) | - | 201.6% | 64.5% | 90.2% | 47.9% | 19.7% | - | - | - | - |
| EBITDA (USD) | 8,822 | (144,568) | (247,953) | (141,739) | (461,562) | (844,875) | - | - | - | - |
| Operating Income (USD) | 6,781 | (157,741) | (303,078) | (279,175) | (641,950) | (1,066,736) | - | - | - | - |
| Operating Margin | 10.4% | (79.9%) | (93.3%) | (45.2%) | (70.2%) | (97.5%) | - | - | - | - |
| % EBITDA Margin | 13.5% | (73.2%) | (76.3%) | (22.9%) | (50.5%) | (77.2%) | - | - | - | - |
| NET Income (USD) | 38,864 | (31,590) | (39,616) | (78,696) | (500,736) | (1,299,540) | (1,648,410) | - | - | - |
| % Net Margin | 59.4% | (16.0%) | (12.2%) | (12.7%) | (54.8%) | (118.8%) | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.